针对SARS-CoV-2的双特异性和三特异性抗体的设计和表征
Jiayang Wang1, Qi Qian2, Yushan Jiang1
1BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China.
Vaccines
|April 23, 2025
概括
新的多种类型抗体显示出治疗COVID-19的前景. 这些新型双特异性和三特异性抗体有效中和SARS-CoV-2变体,并证明了体内治疗效果,为新兴传染病提供了潜在的新疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 生物技术是生物技术.
背景情况:
- 由SARS-CoV-2引起的COVID-19大流行需要新的治疗方法,因为新出现的免疫逃避变种.
- 现有的治疗方法,如单克隆抗体,面临着奥米克朗BA.1,BA.2,XBB.1和EG.5.5等变异的挑战.
- 迫切需要广泛的抗病毒药物来对抗SARS-CoV-2不断变化的威胁.
研究的目的:
- 开发用于COVID-19治疗的新型多种类型抗体.
- 评估针对SARS-CoV-2变种的双特异性和三特异性抗体的疗效.
- 探索抗体工程在应对新兴传染病方面的潜力.
主要方法:
- 重组双特异性 (IgG-scFv) 和三特异性 (Fab片段) 抗体在HEK 293细胞中表达.
- 在试验室中使用伪病毒中和试验评估了疗效.
- 在体内治疗潜力通过BALB/c小鼠的病毒挑战研究来评估.
主要成果:
- 双特异性抗体显示出显著的伪病毒中和,IC50值从8到591 ng/mL.
- 三种特异性抗体表现出优异的中和,IC50值在5至27ng/mL之间.
- 双特异性和三特异性抗体都在SARS-CoV-2感染的小鼠模型中显示出治疗疗效.
结论:
- 开发的多种类型抗体为COVID-19提供了潜在的新疗法选择.
- 多种类型的抗体策略在对抗新兴病毒病原体方面具有重大前景.
- 这项研究有助于开发针对传染病的基于抗体的先进对策.
相关概念视频
Cross-reactivity
30.9K
Overview
30.9K
Conjugated Proteins
18.1K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.1K


